– New Findings Demonstrate 81% of Participants Achieve Durable Biochemical Response by Month 30 with Livdelzi – – Nearly Half of Participants with Primary Biliary Cholangitis (PBC) Achieve Alkaline Phosphatase (ALP) Normalization with Livdelzi – – Livdelzi Reduced Pruritus Severity in PBC Participants and Led to Near Resolution of Itch in 27% of Participants with Moderate to Severe Itch – Gilead Sciences, Inc. (NASDAQ:GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with Livdelzi® (seladelpar) achieved a composite biochemical

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of $750 million of 4.80% senior notes maturing in 2029, $1 billion of 5.10% senior notes maturing in 2035, $1 billion of 5.50% senior notes maturing in 2054 and $750 million of 5.60% senior notes maturing in 2064. The offering is expected to close November 20, 2024, subject to customary closing conditions. Gilead intends to use the net proceeds from this offering for general corpor

Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Healthcare Conference on Wednesday, November 20 at 9:30 AM Greenwich Mean Time Piper Sandler Annual Healthcare Conference on Tuesday, December 3 at 11:00 AM Eastern Time Annual Evercore ISI HealthCONx Conference on Wednesday, December 4 at 11:40 AM Eastern Time The live webcasts can be accessed at the company's investors page at investors.gilead.com. The replays will be available for at least 30 days following the presentation. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakth

Product Sales Excluding Veklury Increased 7% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 13% Year-Over-Year to $3.5 billion Oncology Sales Increased 6% Year-Over-Year to $816 million Gilead Sciences, Inc. (NASDAQ:GILD) announced today its third quarter 2024 results of operations. "Gilead's third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% year-over-year growth for Biktarvy. Based on this very strong topline growth and disciplined operating expense management, we are increasing our full year revenue, operating income, and earnings per share guidance," said Daniel O'Day, Gilead's Chairman and Chief Executive Offic

– Durability of Response and Continued Manageable Safety Profile for the Phase 1 and iMMagine-1 Studies with Anito-cel in Patients with Relapsed/Refractory Multiple Myeloma to be Presented by Partner Arcellx; Follows Progress with First Patient Dosed in Phase 3 iMMagine-3 Study – – Survival Rate for Yescarta® Supported by Largest Real-World Analysis of CAR T for Second-Line Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma – – Durability of Response and Long-Term Survival with Yescarta® and Tecartus® in Multiple Blood Cancers Observed in ZUMA-5, ZUMA-2, and ZUMA-3 Studies – Kite, a Gilead Company (NASDAQ:GILD), will share 18 presentations, including six oral presentation

- Key Insights from Viral Hepatitis, PBC, and MASH/Fibrosis Studies Highlight Gilead's Ongoing Commitment to Advancing Life-Changing Liver Disease Research - Gilead Sciences, Inc. (NASDAQ:GILD) today announced new research to be presented at The Liver Meeting® 2024, hosted by the American Association for the Study of Liver Diseases (AASLD) from November 15-19 in San Diego, Calif. More than 40 abstracts will be presented with key data, including 11 abstracts reporting new data on primary biliary cholangitis (PBC). The data will include findings from the RESPONSE trial that demonstrate the efficacy and safety profile of Livdelzi® (seladelpar) in people living with PBC and compensated cirrhos

Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its third quarter 2024 financial results and guidance will be released on Wednesday, November 6, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's third quarter 2024 financial results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all peop

-  Non-exclusive voluntary license agreement enables the manufacture and distribution of lenacapavir for HIV prevention and treatment of heavily treatment-experienced patients with multi drug-resistant HIV HYDERABAD, India, Oct. 2, 2024 /PRNewswire/ -- Hetero, India's leading pharmaceutical company with the widest global reach, today announced a new partnership with Gilead Sciences Ireland UC (Gilead Sciences, (Nasdaq: GILD)), a non-exclusive, royalty-free voluntary licensing agreement to manufacture and distribute lenacapavir in 120 primarily low- and lower- middle income countries (LMICs). This agreement will broaden access to lenacapavir, the innovative HIV treatment used in combination w

-- Gilead and Genesis Will Leverage the GEMS AI Platform to Generate and Jointly Optimize Molecules Against Selected Targets -- -- Gilead Receives Exclusive Rights to Develop and Commercialize Products from the Collaboration -- Gilead Sciences, Inc. (NASDAQ:GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910912771/en/ Genesis is pioneering generative and predictive artificial intelligence (AI) technologies to help create therapeutic

-Data Span Multiple Types of Lung Cancer and Lines of Therapy- Gilead Sciences, Inc. (NASDAQ:GILD) will present new data from the company's broad lung cancer clinical development program during the IASLC 2024 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, taking place Sept. 7-10, 2024 in San Diego, Calif. Data to be highlighted across three oral presentations include: initial results from two cohorts of the EVOKE-02 study of Trodelvy® (sacituzumab govitecan-hziy) in previously untreated advanced or metastatic non-small cell lung cancer (mNSCLC), results from a subgroup analysis of the EVOKE-01 study of Trodelvy in second-line mNSCLC,

8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

424B5 - GILEAD SCIENCES, INC. (0000882095) (Filer)

FWP - GILEAD SCIENCES, INC. (0000882095) (Subject)

424B5 - GILEAD SCIENCES, INC. (0000882095) (Filer)

10-Q - GILEAD SCIENCES, INC. (0000882095) (Filer)

8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

10-Q - GILEAD SCIENCES, INC. (0000882095) (Filer)

8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215974, Application Classification: Labeling

Submission status for GILEAD SCIENCES INC's drug BIKTARVY (SUPPL-20) with active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 10/08/2024. Application Category: NDA, Application Number: 210251, Application Classification: Manufacturing (CMC)

Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-7) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 215974, Application Classification: Labeling

Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-5) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 215973, Application Classification: Labeling

Submission status for GILEAD SCIENCES INC's drug VEKLURY (SUPPL-27) with active ingredient REMDESIVIR has changed to 'Approval' on 06/27/2024. Application Category: NDA, Application Number: 214787, Application Classification: Labeling

Submission status for GILEAD SCIENCES INC's drug BIKTARVY (SUPPL-19) with active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 04/24/2024. Application Category: NDA, Application Number: 210251, Application Classification: Efficacy

Submission status for GILEAD SCIENCES INC's drug VEMLIDY (SUPPL-17) with active ingredient TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 208464, Application Classification: Efficacy

Submission status for GILEAD SCIENCES INC's drug VEMLIDY (SUPPL-16) with active ingredient TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 208464, Application Classification: Efficacy

Submission status for GILEAD SCIENCES INC's drug VEKLURY (SUPPL-26) with active ingredient REMDESIVIR has changed to 'Approval' on 02/28/2024. Application Category: NDA, Application Number: 214787, Application Classification: Efficacy

4 - GILEAD SCIENCES, INC. (0000882095) (Reporting)

SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

SC 13G - GILEAD SCIENCES, INC. (0000882095) (Subject)

SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)

SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)

SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)

SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)

SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)

High-rolling investors have positioned themselves bullish on Gilead Sciences (NASDAQ:GILD), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in GILD often signals that someone has privileged information. Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment among these major traders is split, with 55% bullish and 33% bearish. Among all the options we identified, there was one put, amounting to $27,798, and 8 calls, totaling $322,062. Expe

New research suggests that Gilead Sciences Inc.’s (NASDAQ:GILD) lenacapavir, sold as Sunlenca in the U.S. for HIV prevention, could cost patients just $40 annually. Currently priced at $42,250 for the first year, campaigners urge the company to significantly reduce costs globally. In December 2022, the FDA approved Lenacapavir in combination with other antiretrovirals to treat HIV-1 infection in heavily treatment-experienced adults with multi-drug resistant HIV-1 infection. At the International AIDS Conference in Munich, experts presented a study estimating that a generic version of lenacapavir could be produced for $40 a year, assuming 10 million people used it annually. The Gua

Tuesday, GSK Plc (NYSE:GSK) / Pfizer Inc (NYSE:PFE)-owned ViiV Healthcare said its two-drug HIV regimen Dovato was as effective as Gilead Science Inc‘s (NASDAQ:GILD) three-drug combo Biktarvy in a head-to-head trial. Japanese pharmaceutical company Shionogi & Company is also a stakeholder in ViiV healthcare. ViiV Healthcare released 48-week findings from PASO DOBLE (GeSIDA 11720 study), the largest head-to-head, phase IV randomized clinical trial (RCT) investigating the 2-drug regimen Dovato (dolutegravir/lamivudine [DTG/3TC]) compared to the 3-drug regime Biktarvy (bictegravir/ emtricitabine/tenofovir alafenamide fumarate [BIC/FTC/TAF]) for virologically suppressed HIV-1 patients.

HC Wainwright analyst initiated coverage on AnaptysBio Inc (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering immunology therapeutics. AnaptysBio has a pipeline of checkpoint agonists, including rosnilimab, a PD-1 agonist in development for rheumatoid arthritis (RA) and ulcerative colitis (UC), and ANB032, a B and T cell lymphocyte attenuator (BTLA) agonist in development for atopic dermatitis (AD). In Phase 1, rosnilimab showed a 90% reduction of T cell proliferation, inflammatory cytokine secretion and PD-1(high) T cells and demonstrated favorable safety. Related: Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Trigge

Gilead Sciences (NASDAQ:GILD) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 8 0 0 Last 30D 0 0 1 0 0 1M Ago 0 1 1 0 0 2M Ago 0 0 2 0 0 3M Ago 1 0 4 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.3, a high estimate of $93.00, and a low estimate of $69.00. A 1.68% drop is evident in the current averag

Cantor Fitzgerald analyst Olivia Brayer maintains Gilead Sciences (NASDAQ:GILD) with a Neutral and lowers the price target from $75 to $70.

Whales with a lot of money to spend have taken a noticeably bullish stance on Gilead Sciences. Looking at options history for Gilead Sciences (NASDAQ:GILD) we detected 9 trades. If we consider the specifics of each trade, it is accurate to state that 44% of the investors opened trades with bullish expectations and 44% with bearish. From the overall spotted trades, 3 are puts, for a total amount of $108,977 and 6, calls, for a total amount of $345,373. What's The Price Target? After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $75.0 for Gilead Sciences, spanning the last three months. Analyzing Volum

Wolfe Research initiated coverage of Gilead Sciences with a rating of Outperform and set a new price target of $110.00

Citigroup initiated coverage of Gilead Sciences with a rating of Buy and set a new price target of $125.00

Maxim Group downgraded Gilead Sciences from Buy to Hold

Leerink Partners upgraded Gilead Sciences from Market Perform to Outperform and set a new price target of $96.00 from $74.00 previously

Bernstein initiated coverage of Gilead Sciences with a rating of Outperform and set a new price target of $105.00

Wells Fargo upgraded Gilead Sciences from Equal Weight to Overweight and set a new price target of $100.00 from $78.00 previously

Raymond James upgraded Gilead Sciences from Mkt Perform to Outperform and set a new price target of $93.00

Maxim Group reiterated coverage of Gilead Sciences with a rating of Buy and set a new price target of $85.00 from $90.00 previously

HSBC Securities upgraded Gilead Sciences from Reduce to Hold and set a new price target of $69.00

Truist downgraded Gilead Sciences from Buy to Hold and set a new price target of $82.00 from $91.00 previously

Product Sales Excluding Veklury Increased 7% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 13% Year-Over-Year to $3.5 billion Oncology Sales Increased 6% Year-Over-Year to $816 million Gilead Sciences, Inc. (NASDAQ:GILD) announced today its third quarter 2024 results of operations. "Gilead's third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% year-over-year growth for Biktarvy. Based on this very strong topline growth and disciplined operating expense management, we are increasing our full year revenue, operating income, and earnings per share guidance," said Daniel O'Day, Gilead's Chairman and Chief Executive Offic

Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its third quarter 2024 financial results and guidance will be released on Wednesday, November 6, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's third quarter 2024 financial results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all peop

Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.7 billion Biktarvy Sales Increased 8% Year-Over-Year to $3.2 billion Oncology Sales Increased 15% Year-Over-Year to $841 million Gilead Sciences, Inc. (NASDAQ:GILD) announced today its second quarter 2024 results of operations. "Gilead has had another strong quarter with 6% year-over-year growth in our base business. This was driven by sales of our therapies for HIV, Oncology and Liver Disease, including 8% growth for Biktarvy," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "One of the key highlights of the quarter was interim data from the Phase 3 PURPOSE 1 trial showing 100% efficacy for lenacapa

Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's second quarter 2024 financial results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all pe

Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billion Biktarvy Sales Increased 10% Year-Over-Year to $2.9 billion Oncology Sales Increased 18% Year-Over-Year to $789 million Closed CymaBay Acquisition Resulting in $3.9 billion Acquired IPR&D Charge ($3.14 Diluted EPS Impact) Gilead Sciences, Inc. (NASDAQ:GILD) announced today its first quarter 2024 results of operations. "Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology and Liver Disease," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "The acquisition of CymaBay brings us another potent

Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its first quarter 2024 financial results and guidance will be released on Thursday, April 25, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2024 financial results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all peop

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared an increase of 2.7% in the company's quarterly cash dividend, beginning in the first quarter of 2024. The increase will result in a quarterly dividend of $0.77 per share of common stock. The dividend is payable on March 28, 2024, to stockholders of record at the close of business on March 15, 2024. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is commi

Product Sales Excluding Veklury Increased Year-Over-Year by 7% for Full Year 2023 Biktarvy Sales Increased Year-Over-Year by 14% for Full Year 2023 Oncology Sales Increased Year-Over-Year by 37% for Full Year 2023 Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results of operations for the fourth quarter and full year 2023. "This was another strong year of revenue growth for Gilead's base business, driven by both HIV and Oncology," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "The strength of the business provides a solid foundation as we enter a new catalyst-rich phase for the company. We are expecting several milestones in 2024, including updates on l

Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its fourth quarter and full year 2023 financial results and guidance will be released on Tuesday, February 6, 2024 after the market closes. At 5:00 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's fourth quarter and full year 2023 financial results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating

Product Sales Excluding Veklury Increased 5% Year-Over-Year to $6.4 billion Biktarvy Sales Increased 12% Year-Over-Year to $3.1 billion Oncology Sales Increased 33% Year-Over-Year to $769 million Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results of operations for the third quarter of 2023. "Gilead has now delivered two years of consistent growth in our base business. In the third quarter, this continued growth was driven by both Virology and Oncology," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "Our clinical momentum also remains strong, and highlights this quarter included new data on Trodelvy with pembrolizumab in first-line metastatic non-smal

Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Thad Huston as Chief Financial Officer (CFO) and Chief Operating Officer (COO) as per 1 July 2023. Mr. Huston will be a member of the Executive Committee of Galapagos and will join Galapagos from Kite, a Gilead Company (NASDAQ:GILD). He brings 30 years of global finance and operational experience in healthcare with an excellent track record of driving business transformation and innovation. "On behalf of the Board of Directors and management of Galapagos, I extend a warm welcome to Thad. Thad is a widely recognized leader with a strong internationa

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead's senior leadership team, effective May 30. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005214/en/Gilead Appoints Cindy Perettie Executive Vice President of Kite (Photo: Business Wire) Ms. Perettie brings with her extensive experience in oncology and a commitment to improving patient care. Most recently, she was Head of Roche's Molecular Lab Solutions where she oversaw the PCR (polymerase chain reactio

MONTREAL, Nov. 29, 2022 /PRNewswire/ - Thryv Therapeutics Inc. is pleased to announce the appointment of Melissa Koomey to its Board of Directors. Ms. Koomey brings an impressive depth of experience in product commercialization, launch and marketing execution, which will be crucial as Thryv advances its development programs in rare arrhythmias such as Long QT Syndrome and advanced cancers. "We are excited to have Melissa join the Thryv Board of Directors at this pivotal time in our story.  Our lead compound will emerge from initial safety studies early in 2023 and we will accelerate into efficacy trials with Melissa's experience and insights in Long QT Syndrome," said Paul F. Truex, Thryv's

– Brett Pletcher, Executive Vice President, Corporate Affairs and General Counsel to Retire After 17 Years at Gilead – Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Deborah Telman will join the company as Executive Vice President, Corporate Affairs and General Counsel, and will become a member of the company's senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O'Day. Ms. Telman will assume responsibility for Gilead's legal and corporate affairs function, which includes government and policy, and public affairs. Ms. Telman will start in her new role August 1, 2022. She will also become Corporate Secretary of Gilead. Ms. Telman will succeed Brett Plet

– Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead – Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Stacey Ma, PhD will join the company as Executive Vice President, Pharmaceutical Development and Manufacturing, and will become a member of the company's senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O'Day. Dr. Ma will assume responsibility for Gilead's Pharmaceutical Development and Manufacturing organization effective July 18, 2022. Dr. Ma will succeed Dr. Yang, who is retiring from Gilead after nearly three decades. Dr. Ma brings to her new role more than 25 years of ex

Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Robin L. Washington as an independent director effective May 12, 2022. Ms. Washington is among the most experienced business leaders in the biopharmaceutical and technology industries, having served as Chief Financial Officer at Gilead, Inc. from 2008 until 2019, managing global finance, investor relations, facilities and operations, and information technology during a period when corporate revenue grew by more than six-fold. This press release features multimedia. View the full

Mr. Allan, the 2017 winner of the prestigious Julia Levy Award, to collaborate with 2021 Julia Levy Award winner Dr. Lakshmi P. Kotra, CEO of FSD Pharma subsidiary Lucid Psycheceuticals FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRE: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced the appointment of David Allan and John McGraw, PhD, MSc, to the Company's Advisory Board. "Mr. Allan and Dr. McGraw both have impressive careers in the field of healthcare and biotechnology underscored by tremendously successful exits and we are excited to welcome them to our team," commented Anthony Durkacz, Foun

NEWARK, N.J., June 14, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE:RFL), a pharmaceutical company focused on developing novel cancer metabolism therapeutics, today announced the appointment of three senior biopharmaceutical leaders to its Board of Directors: Ameet Mallik, Chief Executive Officer of Rafael Holdings; Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc., (NASDAQ GS: MRNA); and Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir Bio. www.rafaelholdings.com (PRNewsfoto/Rafael Holdings, Inc.)" alt="Rafael Holdings holds commercial real estate assets and interests in two clini

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Flavius Martin, MD will join the company as Executive Vice President, Research, and will become a member of the company’s senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O’Day. Dr. Martin will assume responsibility for Gilead’s research organization effective April 12, 2021. Bill Lee, PhD, is retiring from Gilead after three decades. Dr. Martin brings to his new role significant experience overseeing industry-leading research, with particular expertise in oncology and inflammation. He joins Gilead from Amgen, Inc., where he most recently served as Vice Pr

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that Frank Neumann, MD, PhD, has joined the company as Senior Vice President and Global Head of Clinical Development. Dr. Neumann will lead Kite’s Clinical Development organization across hematological malignancies and solid tumors. Ken Takeshita, MD, has decided to leave the company to pursue another opportunity at the end of February. Dr. Neumann, who joins Kite from Verastem, Inc. (also known as Verastem Oncology), brings a record of proven leadership in cell therapy and oncology clinical development. Prior to Verastem, he served as Vice President, Head of Oncology Clinical Research at